Avsar.

Healthcare · Pharmaceuticals

Corona Remedies Ltd (CORONA)

₹2,149.60

Mkt cap
₹13,147 Cr
P/E ratio
59.80
P/B
16.41
Div yield
0.47%
ROE
29.50%
ROCE
33.30%
EPS (TTM)
₹35.95
Book value
₹131
52W range
1,337–2,292
Sector
Healthcare

Price history

Previous close

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. [1]

NSE CORONABSE 544644
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−6.23% from high
₹2,150
₹1,337+60.83% from low₹2,292
Current
₹2,149.60
Prev close
₹2,217.40
Day
−3.06%
Price performance
1D
−1.91%
1W
+6.04%
1M
+4.65%
3M
+4.01%
6M
+28.68%
1Y
—
YTD
+48.92%

Financials

Revenue, profit & margin
P/E ratio
59.8×
CORONA is 76% above the sector median of 34.0×
CORONA59.8×
Sector median34.0×
 Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Trend
Sales314298294347361342353422441
Expenses247228239277283259291329345
Operating Profit676954707883629396
OPM %21%23%18%20%22%24%18%22%22%
Other Income21122-17432
Interest322222133
Depreciation91010999101315
Profit before tax575843617055548081
Tax %25%23%28%24%25%25%17%25%25%
Net Profit434531465241456060
EPS in Rs7.037.325.127.598.536.747.379.839.84
Raw PDF

Earnings

Results dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.33% · closed higher next day 1 of last 1
 Q1FY27Q2FY27
Broadcast31 Jul '26◦30 Oct '26◦
Earnings day+0.33%—
+1 day+2.90%—
+5 days−0.83%—
+15 days+2.39%—
+30 days+5.67%—
FilingXBRLXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Sep 2026
69.00%Promoter
Promoters69.00%
FIIs4.21%0.58
DIIs16.44%3.54
Public10.35%4.12
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,777.7034.664,26,5300.90%1,995−10.53%16,199+11.88%20.53%
Divi's Lab.₹9,780.0087.142,59,6280.31%902+65.50%3,080+27.80%21.97%
Torrent Pharma.₹4,613.4080.831,75,4790.82%534−10.03%4,979+50.79%15.19%
Laurus Labs₹2,405.5097.001,29,9720.08%436+126.43%2,206+33.44%17.76%
Zydus Lifesci.₹1,245.5025.521,24,2390.08%990−35.09%8,017+21.96%21.14%
Dr Reddy's Labs₹1,352.0040.301,12,8490.59%913−31.35%8,698−1.48%13.04%
Cipla₹1,378.9035.871,11,3970.94%852−35.05%7,404−2.44%15.49%
Corona Remedies₹2,149.6059.8213,1470.47%60+15.40%441+22.16%33.29%
Median: 158 Co.₹426.3834.031,9210.08%14+24.68%175+19.54%15.12%

Filings

Annual reports1
Annual Report 2026
Concall transcripts11
PPTOct 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptJan 2026PPTJan 2026RECJan 2026
Credit ratings2
Rating update 9 OctcareRating update 9 Febcare
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 31 OctAnnouncement under Regulation 30 (LODR)-Newspaper Publication 31 Oct - Newspaper Publication of Unaudited Financial Results for the second quarter and half year ended on September 30, 2026Announcement under Regulation 30 (LODR)-Investor Presentation 30 OctAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 30 Oct - Corona Remedies reported Q2FY27 revenue of ₹441.2 crore, up 22%; H1 revenue ₹863.6 crore, plus ANVISA GMP certification.Unaudited Financial Results Along With The Limited Review Reports For Second Quarter And Half Year Ended September 30, 2026 30 Oct - Corona Remedies reported Q2 FY26 revenue of Rs 441.17 crore and net profit of Rs 60.18 crore.